GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hamlet BioPharma AB publ (XSAT:HAMLET B) » Definitions » Capex-to-Operating-Cash-Flow

Hamlet BioPharma AB publ (XSAT:HAMLET B) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Hamlet BioPharma AB publ Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Hamlet BioPharma AB publ's Capital Expenditure for the three months ended in Mar. 2025 was kr0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was kr-10.39 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Hamlet BioPharma AB publ Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hamlet BioPharma AB publ Capex-to-Operating-Cash-Flow Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hamlet BioPharma AB publ Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow falls into.


;
;

Hamlet BioPharma AB publ Capex-to-Operating-Cash-Flow Calculation

Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.278) / -36.002
=N/A

Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -10.389
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hamlet BioPharma AB publ  (XSAT:HAMLET B) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Hamlet BioPharma AB publ Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Hamlet BioPharma AB publ's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Hamlet BioPharma AB publ Business Description

Traded in Other Exchanges
Address
Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.

Hamlet BioPharma AB publ Headlines

No Headlines